Mavoglurant

Drug Profile

Mavoglurant

Alternative Names: AFQ-056

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Alkynes; Antiparkinsonians; Anxiolytics; Esters; Indoles; Nitriles; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obsessive-compulsive disorders
  • No development reported Chorea; Gastro-oesophageal reflux; Smoking withdrawal
  • Discontinued Anxiety disorders; Drug-induced dyskinesia; Fragile X syndrome

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 03 Oct 2016 Novartis plans a phase II trial for Fragile X Syndrome (Children) in USA (NCT02920892)
  • 09 Jun 2016 Novartis terminates a phase-II clinical trials in Obsessive-compulsive disorders in USA, Bulgaria, Czech Republic, Poland, Switzerland, United Kingdom and Germany as the study did not meet its primary efficacy objective(NCT01813019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top